PEDIAPHARM NAPROXEN SUSPENSION 25 MG
NAPROXEN : 25 MG · DIN 02162431 · MEDEXUS PHARMACEUTICALS INC.
Health Canada status: MARKETED
What is PEDIAPHARM NAPROXEN SUSPENSION?
PEDIAPHARM NAPROXEN SUSPENSION 25 MG contains NAPROXEN : 25 MG. It is listed in the Health Canada Drug Product Database under DIN 02162431, held by MEDEXUS PHARMACEUTICALS INC., supplied as SUSPENSION for ORAL administration. Health Canada currently lists it as marketed, status dated 20-Dec-2022. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is PEDIAPHARM NAPROXEN SUSPENSION used for?
The treatment of the signs and symptoms of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and juvenile rheumatoid arthritis. The relief of minor aches and pains in muscles, bones and joints, mild to moderate pain accompanied by inflammation in musculoskeletal injuries (sprains and strains) and primary dysmenorrhea.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
What else is PEDIAPHARM NAPROXEN SUSPENSION called?
The same molecule, NAPROXEN, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Naproxen Bluefish | Latin | Sweden |
| Pronaxen® | Latin | Sweden |
| Napflam | Latin | South Africa |
| Naprosyn | Latin | Australia, South Africa |
| NAROX | Latin | Bahrain |
| Crysanal | Latin | Australia |
| Naproxen Evolan | Latin | Sweden |
| Adco-Naproxen | Latin | South Africa |
| EMOXEN PLUS | Latin | Czechia |
| Nafasol Ec | Latin | South Africa |
| NALGESIN | Latin | Czechia |
| Naprocur | Latin | Sweden |
| Naprosyn® Entero | Latin | Sweden |
| Naproxen Orifarm | Latin | Sweden |
| Phebra Naproxen Suspension | Latin | Australia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Product details and regulatory record
| DIN | 02162431 |
|---|---|
| Brand name | PEDIAPHARM NAPROXEN SUSPENSION |
| Generic / active ingredient | NAPROXEN : 25 MG |
| Manufacturer | MEDEXUS PHARMACEUTICALS INC. |
| Strength | 25 MG |
| Dosage form | SUSPENSION |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | M01AE02 NAPROXEN |
| AHFS class | 28:08.04.92 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 20-Dec-2022 |
| Original market date | 1996-12-31 00:00:00 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 02162431 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2162431 |
| Brand name | PEDIAPHARM NAPROXEN SUSPENSION |
| Active ingredient / INN | NAPROXEN : 25 MG |
| ATC code | M01AE02 |
| ATC anatomical main group | M — Musculo-skeletal system |
| ATC therapeutic subgroup | M01 |
| AHFS class | 28:08.04.92 |
| Health Canada schedule | Prescription |
| Biosimilar biologic | No |
| Market authorization holder | MEDEXUS PHARMACEUTICALS INC. |
How is it administered?
Adults: 250-500 mg BID. Juvenile Arthritis (2-16 years): ~10 mg/kg/day in two divided doses. Use lowest effective dose for shortest duration. Shake gently before use.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
null
How is it supplied?
474 mL polyethyleneterephthalate (PET) bottles
Which pack is which?
| Strength on the label | 25 MG |
|---|---|
| Dosage form | SUSPENSION |
| Route | ORAL |
| Packaging as described in the monograph | 474 mL polyethyleneterephthalate (PET) bottles |
| Storage | null |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Contraindications
CABG surgery peri-operative setting; third trimester of pregnancy; breastfeeding; severe heart failure; hypersensitivity to naproxen/ASA/NSAIDs; active ulcer/GI bleeding; severe renal/liver impairment.
Warnings and precautions
Serious Risk of Cardiovascular (CV) events (MI, stroke) and Gastrointestinal (GI) events (bleeding, ulceration, perforation). Can cause hypertension and fluid retention.
What can be used instead?
Other Canadian products sharing ATC code M01AE02 NAPROXEN. 31 of 125 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ALEVE BACK AND BODY PAIN | 220 MG | CAPSULE | BAYER INC | MARKETED | DIN 02436337 |
| ALEVE CAPLETS | 220 MG | TABLET | BAYER INC | MARKETED | DIN 02301733 |
| ALEVE LIQUID GELS | 220 MG | CAPSULE | BAYER INC | MARKETED | DIN 02361795 |
| ALEVE NIGHTTIME | 220 MG | TABLET | BAYER INC | MARKETED | DIN 02444593 |
| ANAPROX | 275 MG | TABLET | SEARCHLIGHT PHARMA INC | MARKETED | DIN 02162725 |
| ANAPROX DS | 550 MG | TABLET | SEARCHLIGHT PHARMA INC | MARKETED | DIN 02162717 |
| APO-NAPRO-NA | 275 MG | TABLET | APOTEX INC | MARKETED | DIN 00784354 |
| APO-NAPRO-NA DS | 550 MG | TABLET | APOTEX INC | MARKETED | DIN 01940309 |
| APO-NAPROXEN | 250 MG | TABLET | APOTEX INC | MARKETED | DIN 00522651 |
| APO-NAPROXEN | 375 MG | TABLET | APOTEX INC | MARKETED | DIN 00600806 |
Who else supplies NAPROXEN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. NAPROXEN appears in 1493 registered pack listings across 13 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How much does NAPROXEN cost around the world?
NAPROXEN is listed on 16 national price registers Nexara tracks, across 222 pack listings published on 13 different price bases. What each country publishes is set out below.
| Market | What that country publishes | Brands listed | Pack listings | As of |
|---|---|---|---|---|
| United States | acquisition | 8 | 74 | 03 Sep 2026 |
| South Africa | single exit price | 16 | 25 | 01 Sep 2026 |
| Sweden | AIP (pharmacy purchase price) | 9 | 24 | 03 Sep 2026 |
| Australia | ex-manufacturer | 8 | 23 | 08 Sep 2026 |
| Austria | KVP (Kassenverkaufspreis) | 8 | 16 | 03 Sep 2026 |
| Saudi Arabia | public | 11 | 14 | 01 Sep 2026 |
| Bahrain | retail (max) | 5 | 9 | 01 Sep 2026 |
| United Arab Emirates | public | 5 | 6 | 31 Aug 2026 |
| Iceland | max wholesale | 5 | 5 | 02 Sep 2026 |
| Luxembourg | reimbursement | 5 | 5 | 05 Sep 2026 |
| Czechia | max producer price (ex-factory) | 2 | 4 | 03 Sep 2026 |
| United Kingdom | hospital | 4 | 4 | 31 Aug 2026 |
| Hungary | producer price (ex-factory) | 4 | 4 | 03 Sep 2026 |
| Romania | max producer price | 4 | 4 | 03 Sep 2026 |
| Greece | producer price (ex-factory) | 3 | 3 | 03 Sep 2026 |
| Belgium | public | 2 | 2 | 01 Sep 2026 |
Why there are no figures here. These bases are not comparable. A Brazilian ex-factory ceiling, a Belgian pharmacy public price and a Japanese reimbursement rate answer three different questions, and none of them is what a product lands in Canada for. Putting them side by side would mislead in both directions, so Nexara publishes where a molecule is listed and on what basis, and quotes the delivered Canadian price per order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.